UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000036979 |
|---|---|
| Receipt number | R000042129 |
| Scientific Title | A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink |
| Date of disclosure of the study information | 2020/06/09 |
| Last modified on | 2020/10/09 11:51:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink
Acronym
A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink
Scientific Title
A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink
Scientific Title:Acronym
A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To confirm the elevation inhibitory effect of blood glucose and of blood triglyceride by consumption of the test drink.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
*Area under the concentration time curve of blood glucose
*Area under the concentration time curve of blood insulin
Key secondary outcomes
*Area under the concentration time curve of blood triglyceride
*Blood glucose level of each measuring point
*Blood insulin level of each measuring point
*Blood triglyceride level of each measuring point
*Cmax of blood glucose level
*Tmax of blood glucose level
*Cmax of blood insulin level
*Tmax of blood insulin level
*Cmax of blood triglyceride level
*Tmax of blood triglyceride level
*The incidence of side effects and/or adverse events
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Consume one bottle (50 mL) of test drink 5 min before the load food intake. Rest more than 5 days. Consume one bottle (50 mL) of control drink 5 min before the load food intake.
Interventions/Control_2
Consume one bottle (50 mL) of control drink 5 min before the load food intake. Rest more than 5 days. Consume one bottle (50 mL) of test drink 5 min before the load food intake.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 64 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Male and Females aged 20 to 64 when informed consent.
2) Subjects their fasting blood glucose are between 110 and 125 mg/dL or their blood glucose level of 120 min after OGTT are between 140 and 199 mg/dL.
3) Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.
Key exclusion criteria
1) Subjects who are being received treatment and/or medication when informed consent.
2) Subjects who are not able to quit intake medicine, food for specific health, functional food and/or supplement having a possibility of affecting blood glucose level during test period.
3) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period.
4) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ).
5) Subjects who excessive alcohol intake.
6) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work.
7) Subjects who excessive alcohol intake.
8) Subjects who have weak digestive organ and/or have tendency of diarrhea.
9) Subjects who show more than 6.5 % in HbA1c level at preliminary test.
10) Subjects who show more than 160 mg/dL in fasting blood glucose level measured by glucose sensor at preliminary test.
11) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
12) Subjects who donated over 200 mL blood and/or blood components within the last one month to the current study.
13) Subjects who donated over 400mL blood and/or blood components within the last three months to the current study.
14) Females who donated over 400mL blood and/or blood components within the last four months to the current study.
15) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
16) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
17) Others they have been determined ineligible by principal investigator or sub-investigator.
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | Suguru |
| Middle name | |
| Last name | Fujiwara |
Organization
CPCC Company Limited
Division name
Division of Clinical Research
Zip code
101-0047
Address
4F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
TEL
03-5297-3112
cpcc-contact@cpcc.co.jp
Public contact
Name of contact person
| 1st name | Masanori |
| Middle name | |
| Last name | Numa |
Organization
CPCC Company Limited
Division name
Planning & Sales Department
Zip code
101-0047
Address
4F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
TEL
03-5297-3112
Homepage URL
cpcc-contact@cpcc.co.jp
Sponsor or person
Institute
CPCC Company Limited
Institute
Department
Personal name
Funding Source
Organization
Mannanlife Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
Address
2F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan
Tel
03-5297-5548
IRB@cpcc.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 06 | Month | 09 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
10
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 05 | Month | 17 | Day |
Date of IRB
| 2019 | Year | 05 | Month | 17 | Day |
Anticipated trial start date
| 2019 | Year | 06 | Month | 09 | Day |
Last follow-up date
| 2019 | Year | 07 | Month | 13 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 06 | Month | 06 | Day |
Last modified on
| 2020 | Year | 10 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042129
